Pharmacoeconomic evaluation of schizophrenia in Taiwan

Model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs

Yen-Kuang Yang, Yeng Hui Tarn, Ting Ying Wang, Chia Yih Liu, Yi Cheng Laio, Yuan Hwa Chou, Shin Min Lee, Chun Chih Chen

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Antipsychotics are the keystone in schizophrenia treatment. Although the benefits of the new generation of antipsychotics has been demonstrated over the last decade, the issues of patient compliance and higher purchasing price of atypical antipsychotics remain unresolved. Risperidone is the only atypical antipsychotic agent with long-acting formulation. Long-acting risperidone is a water-based injection and it has been associated with a low level of pain. The aim of the present study was to test whether an improvement in compliance with the use of a long-acting risperidone, compared with olanzapine and depot haloperidol, can increase the effectiveness and the cost-effectiveness indexes. An economic comparison model with decision tree, rather than a prospective design with real clinical drug trial, was applied. The unit cost for each medical procedure was obtained from the claimed-database of the Bureau of National Health Insurance in Taiwan. An executive committee simulated the incidence of extrapyramidal side-effects and proposed a therapeutic model for each strategy based on a literature review. The probabilities of treatment response of different agents and those of different mental health states were estimated by the executive committee and 10 senior psychiatrists who were randomly selected. Sensitivity analysis was performed for drug cost-effectiveness and compliance improvement for using long-acting risperidone. The results showed that long-acting risperidone is more cost-effective than either olanzapine or depot haloperidol for treating schizophrenia patients whose conditions are stable and whose illness duration ranges from 1 to 5 years. The comparison model with the Kaplan-Meier decision tree may serve as an alternative to prospectively designed studies for cost-effectiveness of atypical antipsychotics.

Original languageEnglish
Pages (from-to)385-394
Number of pages10
JournalPsychiatry and Clinical Neurosciences
Volume59
Issue number4
DOIs
Publication statusPublished - 2005 Aug 1

Fingerprint

olanzapine
Pharmaceutical Economics
Risperidone
Haloperidol
Taiwan
Antipsychotic Agents
Schizophrenia
Costs and Cost Analysis
Cost-Benefit Analysis
Decision Trees
Economic Models
Drug Costs
National Health Programs
Patient Compliance
Compliance
Psychiatry
Mental Health
Therapeutics
Clinical Trials
Databases

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Yang, Yen-Kuang ; Tarn, Yeng Hui ; Wang, Ting Ying ; Liu, Chia Yih ; Laio, Yi Cheng ; Chou, Yuan Hwa ; Lee, Shin Min ; Chen, Chun Chih. / Pharmacoeconomic evaluation of schizophrenia in Taiwan : Model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. In: Psychiatry and Clinical Neurosciences. 2005 ; Vol. 59, No. 4. pp. 385-394.
@article{c400502db7b442e88ea7887c452a29a3,
title = "Pharmacoeconomic evaluation of schizophrenia in Taiwan: Model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs",
abstract = "Antipsychotics are the keystone in schizophrenia treatment. Although the benefits of the new generation of antipsychotics has been demonstrated over the last decade, the issues of patient compliance and higher purchasing price of atypical antipsychotics remain unresolved. Risperidone is the only atypical antipsychotic agent with long-acting formulation. Long-acting risperidone is a water-based injection and it has been associated with a low level of pain. The aim of the present study was to test whether an improvement in compliance with the use of a long-acting risperidone, compared with olanzapine and depot haloperidol, can increase the effectiveness and the cost-effectiveness indexes. An economic comparison model with decision tree, rather than a prospective design with real clinical drug trial, was applied. The unit cost for each medical procedure was obtained from the claimed-database of the Bureau of National Health Insurance in Taiwan. An executive committee simulated the incidence of extrapyramidal side-effects and proposed a therapeutic model for each strategy based on a literature review. The probabilities of treatment response of different agents and those of different mental health states were estimated by the executive committee and 10 senior psychiatrists who were randomly selected. Sensitivity analysis was performed for drug cost-effectiveness and compliance improvement for using long-acting risperidone. The results showed that long-acting risperidone is more cost-effective than either olanzapine or depot haloperidol for treating schizophrenia patients whose conditions are stable and whose illness duration ranges from 1 to 5 years. The comparison model with the Kaplan-Meier decision tree may serve as an alternative to prospectively designed studies for cost-effectiveness of atypical antipsychotics.",
author = "Yen-Kuang Yang and Tarn, {Yeng Hui} and Wang, {Ting Ying} and Liu, {Chia Yih} and Laio, {Yi Cheng} and Chou, {Yuan Hwa} and Lee, {Shin Min} and Chen, {Chun Chih}",
year = "2005",
month = "8",
day = "1",
doi = "10.1111/j.1440-1819.2005.01390.x",
language = "English",
volume = "59",
pages = "385--394",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",
number = "4",

}

Pharmacoeconomic evaluation of schizophrenia in Taiwan : Model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. / Yang, Yen-Kuang; Tarn, Yeng Hui; Wang, Ting Ying; Liu, Chia Yih; Laio, Yi Cheng; Chou, Yuan Hwa; Lee, Shin Min; Chen, Chun Chih.

In: Psychiatry and Clinical Neurosciences, Vol. 59, No. 4, 01.08.2005, p. 385-394.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacoeconomic evaluation of schizophrenia in Taiwan

T2 - Model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs

AU - Yang, Yen-Kuang

AU - Tarn, Yeng Hui

AU - Wang, Ting Ying

AU - Liu, Chia Yih

AU - Laio, Yi Cheng

AU - Chou, Yuan Hwa

AU - Lee, Shin Min

AU - Chen, Chun Chih

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Antipsychotics are the keystone in schizophrenia treatment. Although the benefits of the new generation of antipsychotics has been demonstrated over the last decade, the issues of patient compliance and higher purchasing price of atypical antipsychotics remain unresolved. Risperidone is the only atypical antipsychotic agent with long-acting formulation. Long-acting risperidone is a water-based injection and it has been associated with a low level of pain. The aim of the present study was to test whether an improvement in compliance with the use of a long-acting risperidone, compared with olanzapine and depot haloperidol, can increase the effectiveness and the cost-effectiveness indexes. An economic comparison model with decision tree, rather than a prospective design with real clinical drug trial, was applied. The unit cost for each medical procedure was obtained from the claimed-database of the Bureau of National Health Insurance in Taiwan. An executive committee simulated the incidence of extrapyramidal side-effects and proposed a therapeutic model for each strategy based on a literature review. The probabilities of treatment response of different agents and those of different mental health states were estimated by the executive committee and 10 senior psychiatrists who were randomly selected. Sensitivity analysis was performed for drug cost-effectiveness and compliance improvement for using long-acting risperidone. The results showed that long-acting risperidone is more cost-effective than either olanzapine or depot haloperidol for treating schizophrenia patients whose conditions are stable and whose illness duration ranges from 1 to 5 years. The comparison model with the Kaplan-Meier decision tree may serve as an alternative to prospectively designed studies for cost-effectiveness of atypical antipsychotics.

AB - Antipsychotics are the keystone in schizophrenia treatment. Although the benefits of the new generation of antipsychotics has been demonstrated over the last decade, the issues of patient compliance and higher purchasing price of atypical antipsychotics remain unresolved. Risperidone is the only atypical antipsychotic agent with long-acting formulation. Long-acting risperidone is a water-based injection and it has been associated with a low level of pain. The aim of the present study was to test whether an improvement in compliance with the use of a long-acting risperidone, compared with olanzapine and depot haloperidol, can increase the effectiveness and the cost-effectiveness indexes. An economic comparison model with decision tree, rather than a prospective design with real clinical drug trial, was applied. The unit cost for each medical procedure was obtained from the claimed-database of the Bureau of National Health Insurance in Taiwan. An executive committee simulated the incidence of extrapyramidal side-effects and proposed a therapeutic model for each strategy based on a literature review. The probabilities of treatment response of different agents and those of different mental health states were estimated by the executive committee and 10 senior psychiatrists who were randomly selected. Sensitivity analysis was performed for drug cost-effectiveness and compliance improvement for using long-acting risperidone. The results showed that long-acting risperidone is more cost-effective than either olanzapine or depot haloperidol for treating schizophrenia patients whose conditions are stable and whose illness duration ranges from 1 to 5 years. The comparison model with the Kaplan-Meier decision tree may serve as an alternative to prospectively designed studies for cost-effectiveness of atypical antipsychotics.

UR - http://www.scopus.com/inward/record.url?scp=23744504652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744504652&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1819.2005.01390.x

DO - 10.1111/j.1440-1819.2005.01390.x

M3 - Article

VL - 59

SP - 385

EP - 394

JO - Psychiatry and Clinical Neurosciences

JF - Psychiatry and Clinical Neurosciences

SN - 1323-1316

IS - 4

ER -